Biblio
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: post-transplant cyclophosphamide to overcome the HLA-matching barrier. Transpl Infect Dis. 2020:e13551.
. Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation. J Allergy Clin Immunol. 2023.
. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia. Front Immunol. 2023;14:1184956.
Clofarabine and Treosulfan as conditioning for matched related and unrelated HSCT: results from the phase II trial "Clo3o". Biol Blood Marrow Transplant. 2019.
Editorial: 50 years of BMT: conditioning regimens and early complications after transplantation. Front Oncol. 2024;14:1369573.
. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023.
High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies. Microorganisms. 2024;12(1).
Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience. Curr Res Transl Med. 2023;71(3):103402.
Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA-matching. Biol Blood Marrow Transplant. 2020.
Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases. J Autoimmun. 2023;136:103024.
The place in therapy of ceftazidime/avibactam and ceftolozane/tazobactam in hematological patients with febrile neutropenia. Int J Antimicrob Agents. 2021:106335.